There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Nektar Therapeutics (NKTR) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0047, or 0.71%, to $0.6634. The Nektar Therapeutics has recorded 45,222 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $0.66 and fluctuated between $0.6799 as its day high and $0.6262 as its day low. The current market capitalization of Nektar Therapeutics is $127.78M. A total of 2.26 million shares were traded on the day, compared to an average of 7.17M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, NKTR has seen 0 BUY and 4 SELL insider trades, representing the acquisition of 0 and the disposition of 66,922 shares. Over the last 12 months, there were 7 BUYs and 19 SELLs from insiders. Insiders purchased 71,400 shares during that period but sold 259,300.
In the most recent transaction, ROBIN HOWARD W sold 19,998 shares of NKTR for 0.78 per share on Aug 16. After the transaction, the President & CEO now owns 919,799 company shares. In a previous transaction on Aug 16, Zalevsky Jonathan sold 9,703 shares at 0.78 per share. NKTR shares that Chief R&D Officer owns now total 283,685.
Among the insiders who sold shares, Wilson Mark Andrew disposed of 7,221 shares on Aug 16 at a per-share price of $0.78. This resulted in the Chief Legal Officer holding 250,959 shares of NKTR after the transaction. In another insider transaction, WHITFIELD ROY A sold 30,000 shares at $0.57 per share on Jun 14. Company shares held by the Director now total 216,250.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for NKTR in the last 3 months, the mean price target is $2.65 with high estimates of $6.00 and low estimates of $0.60. In terms of 52-week highs and lows, NKTR has a high of $4.36 and a low of $0.51.
As of this writing, NKTR has an earnings estimate of $Nektar Therapeutics per share for the current quarter. EPS was calculated based on a consensus of Nutrien Ltd. estimates, with a high estimate of $Nature’s Sunshine Products, Inc per share and a lower estimate of $Nkarta, Inc.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. NKTR’s latest balance sheet shows that the firm has $733.96M in Cash & Short Term Investments as of fiscal 2021. There were $143.18M in debt and $85.20M in liabilities at the time. Its Book Value Per Share was $1.04, while its Total Shareholder’s Equity was $679.51M.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NKTR is Buy with a score of 2.63.